NCT07028528 Levagen+ Efficacy Study on Diabetic Peripheral Neuropathy
| NCT ID | NCT07028528 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | RDC Clinical Pty Ltd |
| Condition | Diabetic Peripheral Neuropathy |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2025-07-01 |
| Primary Completion | 2026-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 80 participants in total. It began in 2025-07-01 with a primary completion date of 2026-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to assess the efficacy of Levagen+ supplementation for the symptoms of diabetic peripheral neuropathy (DPN) in patients with DPN. Participants will have remote visits and attend a local pathology centre for blood draws. They will take the study product for 12 weeks, from baseline to week 12 they will have remote visits every 3 weeks.
Eligibility Criteria
Inclusion Criteria: * Adults aged 18-75 years. * Using prescribed glucose-lowering medications, including oral medications (stable dose for 3 months or more) and/or insulin for diabetes (type 1 or 2). * Scoring12 or more on the Self-reported Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS). * Able to provide informed consent. * Agree not to change current diet and/or exercise frequency or intensity during entire enrolment period. * Agree to not participate in another clinical trial during the study period. * Able to attend an ACL collection centre. Exclusion Criteria: * Peripheral neuropathy due to causes other than diabetes mellitus (e.g. nutritional deficiencies; hereditary sensory neuropathy; paraneoplastic diseases; advanced liver disease; kidney disease; hypothyroidism; prolonged phenytoin, warfarin or immunosuppressive drug use; active infection \[HIV, Lyme disease, Epstein-Barr virus, Hepatitis C, Shingles, Leprosy\]; autoimmune disease \[Sjogren syndrome, Lupus, Rheumatoid arthritis, Guillain-Barre syndrome\]; trauma / injury; toxins \[heavy metals, chemicals\]; antibiotics; or inflammatory conditions \[vasculitis\]). * Serious illness e.g., paraneoplastic diseases, advanced liver disease, kidney disease, hypothyroidism, mood disorders such as depression, anxiety or bipolar disorder, neurological disorders such as MS, or heart conditions, or peripheral vascular disease * Unstable illness e.g., diabetes and thyroid gland dysfunction, hypercholesterolemia * Current malignancy (excluding Basal Cell Carcinoma) or chemotherapy or radiotherapy treatment for malignancy within the previous 2 years. * Currently taking Coumadin (Warfarin), Heparin, Dalteparin, Enoxaparin or other anticoagulation therapy including low dose aspirin * Herbal medicines for pain relief including, but not limited to, medicinal cannabis, willow bark (Salix alba), Boswellia (Boswellia serrata) or turmeric/curcumin (Curcuma longa). * Active smokers, nicotine use or drug (prescription or illegal substances) abuse. * Chronic past and/or current alcohol use (\>14 alcoholic drinks per week) * Females attempting to conceive, pregnant or lactating * Allergic, sensitive or intolerant to any of the ingredients in active or placebo formula. * Difficulty swallowing capsules. * Participants who are currently participating in any other clinical trial or who have participated in any other clinical trial during the past 1 month. * Any condition which in the opinion of the investigator makes the participant unsuitable for inclusion.
Contact & Investigator
Ramasamy Venkatesh
STUDY DIRECTOR
Gencor Pacific
Frequently Asked Questions
Who can join the NCT07028528 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Diabetic Peripheral Neuropathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07028528 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07028528 currently recruiting?
Yes, NCT07028528 is actively recruiting participants. Contact the research team at research@rdcglobal.com.au for enrollment information.
Where is the NCT07028528 trial being conducted?
This trial is being conducted at Fortitude Valley, Australia.
Who is sponsoring the NCT07028528 clinical trial?
NCT07028528 is sponsored by RDC Clinical Pty Ltd. The principal investigator is Ramasamy Venkatesh at Gencor Pacific. The trial plans to enroll 80 participants.